Meta’s Reported $95 Billion AI Funding Push Raises the Capital-Spending Stakes
Meta’s reported plan to raise $95 billion for AI infrastructure puts capital spending, leverage and funding durability under the microscope.
SciSparc Stock Jumps 38.56% as Traders Track SCI-110 and AI Pivot
SciSparc shares rose 38.56% as traders focused on the SCI-110 trial and an AI pivot, though confirme…
Aurora Cannabis Investors Weigh Alberta Securities Commission Decision
The Alberta Securities Commission dismissed a Curaleaf application, giving Aurora investors a regula…
Acuity’s $675 Million Parameter Technologies Deal Expands Distech Controls
Acuity’s $675 million acquisition of Parameter Technologies would expand Distech Controls and put cl…
Neurocrine’s Tardive Dyskinesia Opportunity Could Support a Multi-Year Growth Runway
Neurocrine’s estimated 800,000-person tardive dyskinesia population could support years of prescript…
BioNTech and Bristol Myers Squibb Trial Data Put Oncology Pipelines in Focus
New lung cancer trial data from BioNTech and Bristol Myers Squibb shifts attention to pipeline quali…
AbbVie’s Skyrizi Expansion Gives Investors a New Test of Immunology Growth
A new subcutaneous induction option could strengthen Skyrizi’s role in AbbVie’s post-Humira strategy…
Parabilis’ FDA Alignment Gives Its Desmoid Tumor Program a Clearer Road Map
Parabilis’ FDA-aligned dose strategy and placebo-controlled pivotal trial design may reduce uncertai…
Compass Therapeutics’ Tovecimig Data Published in Journal of Clinical Oncology
Peer-reviewed publication of Compass Therapeutics’ Phase 2/3 tovecimig study may shape investor sent…
Zymeworks’ ZW191 Posts Strong Response Rates in Platinum-Resistant Ovarian Cancer
ZW191 produced confirmed response rates of 64.5% and 55.3% in a difficult-to-treat ovarian cancer tr…